Form 4: Milestone Pharma CMO Reports Share Transactions

Milestone Pharmaceuticals' Chief Medical Officer, David Bharucha, reported the vesting of performance and restricted stock units, along with subsequent share sales to cover tax obligations, and the grant of new stock options.

Summary

• David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals Inc. (MIST), reported multiple transactions involving the company's common shares and derivative securities.
• On December 12, 2025, 100,000 common shares vested from a Performance Stock Unit (PSU) award, triggered by the U.S. Food and Drug Administration's (FDA) approval of Cardamyst (etripamil).
• Also on December 12, 2025, Mr. Bharucha was granted 100,000 Employee Stock Options with an exercise price of $1.74, vesting 50% on June 12, 2026, and 50% on December 12, 2026.
• On December 15, 2025, 58,007 common shares were sold at a weighted average price of $2.32 to satisfy income tax liabilities incurred from the PSU vesting.
• On January 26, 2026, 20,100 common shares vested from a Restricted Stock Unit (RSU) award.
• On January 26, 2026, 12,245 common shares were sold at a weighted average price of $1.93 to satisfy income tax liabilities incurred from the RSU vesting.
• Following these transactions, Mr. Bharucha beneficially owns 113,181 direct common shares, 100,000 employee stock options, and 60,300 restricted stock units.

Sentiment

Score: 7

Explanation: The filing indicates a positive development with the FDA approval of Cardamyst (etripamil), which triggered PSU vesting. While there were share sales, they were for tax purposes (sell-to-cover), which is a common and expected practice. The grant of new stock options also reflects continued incentive alignment.

Positives

• The vesting of 100,000 Performance Stock Units (PSUs) was contingent upon and triggered by the U.S. FDA's New Drug Application Approval Letter for Cardamyst (etripamil), indicating a significant regulatory milestone for the company.
• The grant of 100,000 new Employee Stock Options demonstrates continued incentive alignment between management and shareholder interests.

Negatives

• A total of 70,252 common shares were disposed of through 'sell-to-cover' arrangements on December 15, 2025 (58,007 shares at $2.32) and January 26, 2026 (12,245 shares at $1.93), which reduces the direct beneficial ownership of the Chief Medical Officer.

Risks

• The price reported for share dispositions is a weighted average, indicating sales occurred at multiple prices, which could reflect market volatility around the transaction dates.

Future Outlook

The vesting schedules for the newly granted employee stock options extend through December 2026, and for the remaining restricted stock units through January 2029, indicating a long-term incentive structure for the Chief Medical Officer. The successful FDA approval of Cardamyst (etripamil) is a key forward-looking event that has already materialized, triggering PSU vesting.

Management Comments

• The Performance Stock Unit (PSU) award vested upon the certification by the Compensation Committee of the Board of Directors that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil).
• Shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit (RSU) awards only.
• The price reported for share dispositions is a weighted average price, and the Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price upon request.

Industry Context

The FDA approval of Cardamyst (etripamil) is a significant event for Milestone Pharmaceuticals, a pharmaceutical company. Such regulatory approvals are critical milestones in the biopharmaceutical industry, validating a drug's efficacy and safety, and opening pathways for commercialization. This event typically signals a positive development for the company's product pipeline and revenue potential, aligning with broader industry trends of bringing new therapies to market.

Comparison to Industry Standards

• The vesting of performance-based awards tied to regulatory milestones like FDA approval is a common practice in the pharmaceutical industry, aligning executive compensation with critical company achievements, similar to how other biotech firms structure their incentive plans for drug development success.
• The use of 'sell-to-cover' transactions to satisfy tax obligations upon equity award vesting is a standard and widely accepted practice for executives across various industries, including pharmaceuticals, to manage tax liabilities without requiring personal cash outlays.

Stakeholder Impact

• Shareholders: The FDA approval of Cardamyst (etripamil) is a significant positive, potentially increasing the company's value and future revenue streams. Insider sales, though for tax purposes, might be viewed with caution but are generally understood in this context.
• Employees: The vesting of equity awards and grant of new options serve as incentives, potentially boosting morale and retention, especially for key executives.
• Customers/Patients: The FDA approval of Cardamyst (etripamil) means a new treatment option will become available, directly benefiting patients.

Next Steps

• Future vesting of 50% of employee stock options on June 12, 2026.
• Future vesting of the remaining 50% of employee stock options on December 12, 2026.
• Future vesting of remaining Restricted Stock Units on January 26, 2027, January 26, 2028, and January 26, 2029.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, Form 4, Insider Transaction, David Bharucha, Chief Medical Officer, Performance Stock Unit, PSU, Restricted Stock Unit, RSU, Employee Stock Option, FDA Approval, Cardamyst, etripamil, Sell-to-Cover, Beneficial Ownership